LenioBio is a life sciences biotech company, pioneering a disruptive protein expression platform.
Using our ALiCE® technology, we enable our customers – researchers and biopharma manufacturers -to streamline and accelerate their protein discovery, development, and production processes.
We aim to simplify manufacturing and speed up the delivering drugs to the patient.
Our Origins
Embarking on a remarkable journey, our story finds its roots during the 2015 Ebola pandemic. Driven by an unwavering commitment to address urgent demands for essential medicines, we are dedicated to making a profound impact on global health and well-being.
Our Journey
Today, our customized protein service and cell-free lysate products empower academic, biotech, and pharma customers worldwide to conquer their protein production challenges. See how we got to where we are today.
Our People Are Our Greatest Asset
We are an international group of scientists and business experts, committed to pushing the boundaries of protein science further to improve the everyday for 8 billion of us.
Social Responsibility
As a company, we recognize the importance of social responsibility and the role it plays in building a sustainable future for all. We believe that it is our duty to not only operate in an ethical and environmentally conscious manner but also to actively give back to our community and society as a whole.
At LenioBio, we are committed to making a positive impact in the world by supporting various social causes and initiatives. We understand that our success is directly tied to the well-being of the communities we serve, and we strive to be a responsible corporate citizen at all times.
Our People
We are developing products for the whole world, so they need to be designed by minds representing the whole world. It just makes sense. Our team is incredibly diverse and made up of over fourteen different nations!
Access to Healthcare
We were founded on a vision of making bio-therapeutics available to all, regardless of wealth. We firmly believe that our ALiCE technology can help reduce healthcare inequities by enabling distributed manufacturing and bringing medicines closer to those who need them the most.
Environment
The pharmaceutical industry is among the world’s largest carbon emitters. The operational footprint of our ALiCE technology is small and so enables significant reductions in carbon emissions associated with drug manufacturing and distribution.
Related Content
Press release
Stay up-to-date with the latest news and announcements from LenioBio.
Careers
Do you want to be part of the future of biopharma manufacturing?
Contact us
Got a question for our team? We'd love to hear from you.